Hong DS - Search Results

1

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.

Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Dy GK, et al. Among authors: hong ds. J Clin Oncol. 2023 Jun 20;41(18):3311-3317. doi: 10.1200/JCO.22.02524. Epub 2023 Apr 25. J Clin Oncol. 2023. PMID: 37098232 Free PMC article.

2

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience.

Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Moroney J, et al. Gynecol Oncol. 2010 Jun;117(3):467-72. doi: 10.1016/j.ygyno.2010.02.008. Epub 2010 Mar 26. Gynecol Oncol. 2010. PMID: 20347123 Free PMC article. Clinical Trial.

3

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.

Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Garrido-Laguna I, et al. Among authors: hong ds. Clin Cancer Res. 2010 Aug 1;16(15):4031-7. doi: 10.1158/1078-0432.CCR-10-0672. Epub 2010 Jun 4. Clin Cancer Res. 2010. PMID: 20525754

4

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Among authors: hong ds. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.

5

Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience.

Naing A, Stephen SK, Frenkel M, Chandhasin C, Hong DS, Lei X, Falchook G, Wheler JJ, Fu S, Kurzrock R. Naing A, et al. Among authors: hong ds. Cancer. 2011 Nov 15;117(22):5142-50. doi: 10.1002/cncr.26164. Epub 2011 Apr 28. Cancer. 2011. PMID: 21538342 Free article.

6

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.

Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Fu S, et al. Among authors: hong ds. Mol Cancer Ther. 2011 Jul;10(7):1300-7. doi: 10.1158/1535-7163.MCT-11-0259. Epub 2011 May 13. Mol Cancer Ther. 2011. PMID: 21571911 Clinical Trial.

7

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Kurzrock R, et al. Among authors: hong ds. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606412 Free PMC article. Clinical Trial.

8

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Garrido-Laguna I, et al. Among authors: hong ds. Cancer. 2012 Mar 1;118(5):1422-8. doi: 10.1002/cncr.26413. Epub 2011 Aug 5. Cancer. 2012. PMID: 21823111 Free article.

9

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. Janku F, et al. Among authors: hong ds. PLoS One. 2011;6(7):e22769. doi: 10.1371/journal.pone.0022769. Epub 2011 Jul 29. PLoS One. 2011. PMID: 21829508 Free PMC article.

10

Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program.

Fu S, Hong DS, Naing A, Wheler J, Falchook G, Wen S, Howard A, Barber D, Nates J, Price K, Kurzrock R. Fu S, et al. Among authors: hong ds. J Clin Oncol. 2011 Sep 10;29(26):3547-52. doi: 10.1200/JCO.2010.33.3823. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

499 results

Search Page